Sanofi and Regeneron eye extending Dupixent US patent to 2033
Market talk says Sanofi and Regeneron could extend Dupixent’s U.S. patent by two years to 2033, with RBC Capital Markets citing a 70% chance in a research note.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.